Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition

Leukemia

Volumn 28, Issue 10, 2014, Pages 2112-2115

  Gordon, G W ^a   Monge, J ^b   Channon, M B ^a   Wu, Q ^b   Skulan, J L ^c   Anbar, A D ^a,c   Fonseca, R ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; HEMOGLOBIN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; TUMOR MARKER;

AGED; BLOOD ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; BONE; CELL PROLIFERATION; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; BONE AND BONES; CALCIUM ISOTOPES; CELL PROLIFERATION; DIPHOSPHONATES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84921712811     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.193     Document Type: Letter

References (15)

1. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proc 2005; 80: 1371-1382
2. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 226-235
3. Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N et al. International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. J Clin Oncol 2013
4. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998; 103: 902-910
5. Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007; 43: 1670-1678
6. Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009; 14: 276-283
7. Roodman GD. Skeletal imaging and management of bone disease. Hematology 2008 313-319
8. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545-1556
9. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89: 567-577
10. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010; 24: 1700-1712
11. Morgan JL, Skulan JL, Gordon GW, Romaniello SJ, Smith SM, Anbar AD. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci USA 2012; 109: 9989-9994
12. Skulan J, Bullen T, Anbar AD, Puzas JE, Shackelford L, LeBlanc A et al. Natural calcium isotopic composition of urine as a marker of bone mineral balance. Clin Chem 2007; 53: 1155-1158
13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473
14. Morgan JL, Gordon GW, Arrua RC, Skulan JL, Anbar AD, Bullen TD. High-precision measurement of variations in calcium isotope ratios in urine by multiple collector inductively coupled plasma mass spectrometry. Anal Chem 2011; 83: 6956-6962
15. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007; 21: 255-265.